NCT04826341
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ATM, BRCA+, CDK, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on at least one prior chemotherapy; Breast cancer patients are only eligible for phase 1
Exclusions: Patients with unstable brain metastases that require treatment- see trial for details; Patients with variants of uncertain significance (VUS) of the mutations listed
https://ClinicalTrials.gov/show/NCT04826341